Binex

바이넥스 · 053030

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$201.3M (₩277.8B)

Overview

Binex makes conventional pharmaceutical products, including digestive health tablets and eye drops, and also provides contract development and manufacturing services for biologic medicines, meaning it handles production on behalf of other drug companies.

Its pharmaceutical products are supplied to the domestic Korean market, while its biologics contract manufacturing services target both domestic and international clients. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates two distinct business lines: a chemical pharmaceuticals division anchored by a small number of core products, and a biologics contract manufacturing division run out of dedicated facilities.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$122.1M

▲ +29.6% YoY

Operating profit · FY2025

−US$3.3M

Loss narrowed

Net income · FY2025

−US$2.4M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$112.2M(₩154.8B)	US$94.2M(₩130.1B)	US$122.1M(₩168.5B)
Operating profit	US$755.3K(₩1B)	−US$22.3M(−₩30.8B)	−US$3.3M(−₩4.5B)
Net income	US$3.3M(₩4.6B)	−US$25.5M(−₩35.2B)	−US$2.4M(−₩3.3B)

Revenue

FY2023US$112.2M
FY2024US$94.2M
FY2025US$122.1M

Operating profit

FY2023US$755.3K
FY2024−US$22.3M
FY2025−US$3.3M

Net income

FY2023US$3.3M
FY2024−US$25.5M
FY2025−US$2.4M

Key ratios (FY2025)

ROE

-1.8%

Debt/Eq

66.1%

Op. margin

-2.7%

Net margin

-1.9%

Rev. YoY

▲ +29.6%

Why it matters

Binex describes itself as Korea's first biologics contract development and manufacturing organization (CDMO), with its facilities having passed regulatory inspections by health authorities in the United States, Europe, and Japan.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?